{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:50:27Z","timestamp":1778482227033,"version":"3.51.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      Fibroblast activation protein (FAP)-targeted radiopharmaceuticals show promise in cancer imaging, but optimization and development of new radiopharmaceuticals to enhance tumor targeting, prolong retention, and improve diagnostic\/therapeutic outcomes are ongoing. This study aims to evaluate the biodistribution, pharmacokinetics, dosimetry, and safety of a novel FAP-targeted probe\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 in humans, and to preliminarily assess its ability to detect malignant tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Eight patients with solid tumors underwent positron emission tomography\/computed tomography (PET\/CT) scans at multiple time points after intravenous injection of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 (0.05\u20130.1\u00a0mCi\/kg). Regions of interest (ROIs) were drawn on different tissues. Blood and urine samples were collected for analyzing the biodistribution, pharmacokinetics, and radiation dose. The safety of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 and its ability to detect malignant tumors were also evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The biodistribution of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 in humans was similar to that of other\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labeled FAP-targeted probes, with relatively high physiological uptake in the pancreas and uterus. The probe was mainly excreted through the urinary system, with relatively rapid renal excretion and blood clearance rates. Its blood elimination half-life (\n                      <jats:italic toggle=\"yes\">T<\/jats:italic>\n                      <jats:sub>1\/2<\/jats:sub>\n                      ) was 24.66 minutes. The total effective dose of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 in humans was 1.17E\u221202 mSv\/MBq. No serious adverse events were observed.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 PET\/CT clearly detected primary tumors and metastases in all patients. Various lesions showed high\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 uptake as early as 10 minutes postinjection. The maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) increased gradually, and stabilized within 60\u2013120 minutes. Both tumor-to-liver ratio (TLR) and tumor-to-blood ratio (TBR) increased continuously, showing a favorable target-to-background ratio.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The novel FAP-targeted probe\n                      <jats:sup>68<\/jats:sup>\n                      Ga-FAP-75 exhibits favorable biodistribution, pharmacokinetics, and safety, with good tumor specificity and a favorable tumor-to-background ratio, showing great potential in tumor imaging and radionuclide-targeted therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006157","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:00:12Z","timestamp":1767207612000},"page":"211-219","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["First-in-Human Study of 68Ga-FAP-75 PET Imaging of Cancer-associated Fibroblasts"],"prefix":"10.1097","volume":"51","author":[{"given":"Chunxia","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Hubei Key Laboratory of Molecular Imaging"},{"name":"Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhu","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Hubei Key Laboratory of Molecular Imaging"},{"name":"Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6766-5240","authenticated-orcid":false,"given":"Yongkang","family":"Gai","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Hubei Key Laboratory of Molecular Imaging"},{"name":"Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Hubei Key Laboratory of Molecular Imaging"},{"name":"Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Oncology and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Oncology and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-8682","authenticated-orcid":false,"given":"Yuchen","family":"Jin","sequence":"additional","affiliation":[{"name":"Medical Oncology and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5851-4856","authenticated-orcid":false,"given":"Yuanyuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feihu","family":"Guo","sequence":"additional","affiliation":[{"name":"Pharmaceutical Division, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MengTing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Hubei Key Laboratory of Molecular Imaging"},{"name":"Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7263-7399","authenticated-orcid":false,"given":"Xiaoli","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Hubei Key Laboratory of Molecular Imaging"},{"name":"Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"R1-20260203","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"key":"R2-20260203","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.molmet.2016.07.003","article-title":"Fibroblast activation protein (FAP) as a novel metabolic target","volume":"5","author":"S\u00e1nchez-Garrido","year":"2016","journal-title":"Mol Metab"},{"key":"R3-20260203","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","article-title":"Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond","volume":"49","author":"Li","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260203","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260203","doi-asserted-by":"crossref","first-page":"e220749","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"R6-20260203","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R7-20260203","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.2967\/jnumed.123.266046","article-title":"Impact of (68)Ga-FAPI PET\/CT on staging and oncologic management in a cohort of 226 patients with various cancers","volume":"64","author":"Koerber","year":"2023","journal-title":"J Nucl Med"},{"key":"R8-20260203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"(68)Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"R9-20260203","doi-asserted-by":"crossref","first-page":"651005","DOI":"10.3389\/fonc.2021.651005","article-title":"Dynamic PET\/CT imaging of (68)Ga-FAPI-04 in Chinese subjects","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"R10-20260203","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients","volume":"61","author":"Meyer","year":"2020","journal-title":"J Nucl Med"},{"key":"R11-20260203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either (18)F-AlF or Cold-Kit (68)Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J Nucl Med"},{"key":"R12-20260203","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00259-023-06338-6","article-title":"Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?","volume":"50","author":"Chakravarty","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20260203","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","article-title":"Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET\/CT in patients with various cancers","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20260203","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.7150\/thno.79144","article-title":"Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD","volume":"12","author":"Zang","year":"2022","journal-title":"Theranostics"},{"key":"R15-20260203","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2967\/jnumed.121.263016","article-title":"Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer","volume":"63","author":"Zhao","year":"2022","journal-title":"J Nucl Med"},{"key":"R16-20260203","first-page":"26-33.","article-title":"SNMMI procedure standard\/EANM practice guideline for fibroblast activation protein (FAP) PET","volume":"66(1)","author":"Hope","year":"2025","journal-title":"J Nucl Med"},{"key":"R17-20260203","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1007\/s00259-023-06246-9","article-title":"FAP expression in alpha cells of Langherhans insulae\u2014implications for FAPI radiopharmaceuticals\u2019 use","volume":"50","author":"Kirienko","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-20260203","doi-asserted-by":"crossref","first-page":"5301.","DOI":"10.3390\/cancers14215301","article-title":"Subclass analysis of malignant, inflammatory and degenerative pathologies based on multiple timepoint FAPI-PET acquisitions using FAPI-02, FAPI-46 and FAPI-74","volume":"14(21)","author":"Glatting","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"R19-20260203","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1007\/s00259-025-07141-1","article-title":"Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study.","volume":"52","author":"Bilinska","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20260203","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00259-021-05194-6","article-title":"Non-malignant findings of focal (68)Ga-FAPI-04 uptake in pancreas","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20260203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/14737140.2023.2213890","article-title":"Radiolabeled FAPI in pancreatic cancer: can it be an additional value in the management of patients?","volume":"23","author":"Evangelista","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"R22-20260203","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.121.262808","article-title":"Pitfalls and common findings in (68)Ga-FAPI PET: a pictorial analysis","volume":"63","author":"Kessler","year":"2022","journal-title":"J Nucl Med"},{"key":"R23-20260203","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","article-title":"(68)Ga-FAPI-PET\/CT in patients with various gynecological malignancies","volume":"48","author":"Dendl","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20260203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RLU.0000000000003968","article-title":"Uterine uptake of 68Ga-FAPI-04 in uterine pathology and physiology","volume":"47","author":"Zhang","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R26-20260203","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2967\/jnumed.123.267281","article-title":"(68)Ga-FAP-2286 PET of solid tumors: biodistribution, dosimetry, and comparison with (18)F-FDG","volume":"65","author":"Kline","year":"2024","journal-title":"J Nucl Med"},{"key":"R27-20260203","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.21037\/qims-22-1418","article-title":"Biodistribution and radiation dosimetry of multiple tracers on total-body positron emission tomography\/computed tomography","volume":"13","author":"Li","year":"2023","journal-title":"Quant Imaging Med Surg"},{"key":"R28-20260203","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","article-title":"Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study","volume":"63","author":"Mona","year":"2022","journal-title":"J Nucl Med"},{"key":"R29-20260203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12149-025-02022-x","article-title":"FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?","volume":"39","author":"Garc\u00eda Meg\u00edas","year":"2025","journal-title":"Ann Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:00:26Z","timestamp":1770141626000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006157"}},"subtitle":["Biodistribution, Radiation Dosimetry, and Tumor Delineation"],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006157","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2025-05-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}